Indiana hospitals starting to fill ICU beds again
The availability of ICU beds has fallen in recent weeks as hospitals have deactivated hundreds of beds while the number of COVID-19 hospitalizations has climbed.
The availability of ICU beds has fallen in recent weeks as hospitals have deactivated hundreds of beds while the number of COVID-19 hospitalizations has climbed.
Almost a quarter of the nursing home deaths from COVID-19 in Indiana have occurred at facilities operated by Health and Hospital Corporation of Marion County. The facilities are managed by Indianapolis-based American Senior Communities.
Carmel-based MBX Biosciences Inc., co-founded by serial entrepreneur Richard DiMarchi, aims to develop therapeutics to treat rare endocrine disorders.
In direct response to the high levels of stress and anxiety due to the pandemic, Indiana officials on Monday launched a crisis hotline, which will allow Hoosiers to speak confidentially with a trained counselor at any hour free of charge.
The codes are critical to help track the virus by allowing health systems and public health officials around the world seamlessly exchange information.
The increase is hitting more young people. People under 30 now account for 22% of all who have tested positive for COVID-19 in Indiana, up from 15% just a few weeks ago.
A subsidiary of Swiss drug giant Novartis AG announced plans Tuesday to build a targeted radioligand therapy plant at Purdue Research Park near Indianapolis International Airport.
In Touch Pharmaceuticals serves long-term-care facilities in Illinois, Indiana and Michigan. It credits its system for helping clients reduce medication errors, cut waste and reduce costs.
West Lafayette-based Bioanalytical Systems’ latest executive departure comes amid recent signs of stability, turnaround and growth for a company that just three years ago was on the verge of sinking.
The pharmaceutical company said the Roundup settlement would “bring closure to approximately 75%” of the current 125,000 claims against subsidiary Monsanto.
The Hoosier state has 17,093 industry jobs spread out among 69 companies, from Indianapolis-based drugmaker Eli Lilly and Co. to startups scattered around the state, but mostly in clusters near research universities.
The Indianapolis-based insurer says the treatments are “investigational”—or still under clinical study—but a California woman claims the electrical stimulation is FDA-approved and supported by numerous studies.
Taltz rang up sales of $1.3 billion last year, an increase of 46%, making it Lilly’s fastest-growing drug. An estimated 137,000 patients have been treated with Taltz worldwide since its launch four years ago.
Philip and Martin Low’s latest venture, Eradivir, was incorporated in February to develop a treatment that would fight the influenza virus, but COVID-19 prompted a tweak to the business plan.
The design of the long-anticipated project was originally set to be unveiled by the end of 2018, but has been delayed several times—most recently this spring, as the pandemic began to sweep across the United States.
Gov. Eric Holcomb lifted the ban effective Monday, with some caveats, such as making sure that hospitals keep enough personnel and personal protective equipment on hand for COVID-19 patients.
The two technologies are different, but the goal of both is to provide a result within 40 minutes. The researchers say they are working with manufacturers to develop the products, which they hope will retail for $5 or less.
Baricitinib, also known under the brand name Olumiant, is approved in more than 65 countries as a treatment for adults with moderately to severely active rheumatoid arthritis.
State officials declined to provide details on specifically how the hotel is being used—including whether it is a treatment site for homeless individuals—to protect patient privacy.
The long-planned $500 million project is at a pivotal moment—one its organizers say could serve as a catalyst for tremendous growth at the 50-acre campus and for central Indiana overall.